35 studies on Tesamorelin curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified.
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Hk Peptides | 30 | 99.38% | View COA → |
| Shanghai Sigma Audley Ssa | 29 | 96.03% | View COA → |
| Nexaph | 25 | 97.44% | View COA → |
| Wuhan Wansheng Biotechnology | 24 | 93.89% | View COA → |
| Allen Biotechnology Co Abc | 23 | 97.94% | View COA → |
| Qing Li Peptide | 19 | 96.69% | View COA → |
| Lilipeptide | 18 | 96.06% | View COA → |
| Reta Peptide | 17 | 98.77% | View COA → |
Recent certificates: #14733 (99.8%) · #14728 (99.6%) · #14726 (99.6%) · #14729 (99.8%) · #14730 (99.9%) · #14732 (99.7%)
Manufacturers with published third-party certificates of analysis for Tesamorelin. Open a vendor to see every batch we've verified.
This case report underscores that personalized treatment strategies are crucial for managing EVAF in PLWH. For peptide users and clinicians, it reinforces that Tesamorelin and GLP-1R agonists are not interchangeable b…
This review highlights a critical distinction for peptide users and clinicians: only GLP-1R agonists currently possess reproducible, high-quality evidence for a specific musculoskeletal indication (knee osteoarthritis…
The premature termination of this 10-year observational study means that crucial long-term safety data for Tesamorelin in HIV-associated abdominal lipohypertrophy remains largely uncollected. This is significant becau…
These findings are crucial for developing targeted interventions to improve HCV treatment uptake and cure rates among vulnerable HIV/HCV co-infected populations. By understanding the specific barriers faced by untreat…
The early termination of this study represents a missed opportunity to explore a potential therapeutic avenue for COPD-related muscle wasting, a condition with significant unmet medical needs. Tesamorelin, a synthetic…
Peripheral nerve injuries often result in debilitating long-term deficits, making effective therapeutic interventions critically important. If Tesamorelin proves successful in this trial, it could represent a novel ph…
The successful outcome of this trial could represent a significant advancement in managing HIV-associated neurocognitive disorders (HAND), which are a growing concern in the aging HIV population. If tesamorelin proves…
This study highlights the GHRH analog as a promising therapeutic candidate for NAFLD and NASH, offering a novel approach to combat liver inflammation and damage. By targeting immune activation and multiple detrimental…
This analysis provides strong evidence that tesamorelin can be broadly considered for treating excess visceral adipose tissue in people with HIV, irrespective of the presence of dorsocervical fat. This simplifies clin…
These findings underscore the critical need for continued research into HIV's impact on the central nervous system, even in the era of effective ART, and highlight the multifaceted nature of neuropsychiatric complicat…
This study provides critical evidence linking specific medications to Carpal Tunnel Syndrome, highlighting a previously underrecognized risk. The findings could lead to updated prescribing guidelines and enhanced pati…
These findings are highly significant, as they suggest that Tesamorelin, a growth hormone-releasing hormone (GHRH) analog, could offer a novel therapeutic strategy for a debilitating comorbidity in PLWH. The dual bene…
This comprehensive review is crucial for raising awareness among clinicians about the high burden of MASLD in PLWH and its potential for severe liver outcomes. By consolidating current knowledge, it provides a valuabl…
This meta-analysis provides robust evidence supporting Tesamorelin as a highly effective and safe therapeutic option for managing HIV-associated lipodystrophy. The comprehensive improvements in body composition, parti…
The preservation of lean body mass during weight loss is a critical factor for long-term health, metabolic function, and sustained weight management. This study's findings demonstrate that MyoPreserve offers a novel p…
This research highlights a critical interaction between cART and dietary patterns, suggesting that certain high-calorie diets may exacerbate the cardiotoxic effects of antiretroviral drugs. The findings underscore the…
The termination of this Phase 4 clinical trial means a critical knowledge gap remains regarding the long-term ocular safety of tesamorelin in HIV-infected patients with diabetes. Understanding the potential risks or b…
The ability of Tesamorelin to specifically reduce visceral fat represents a significant advancement in managing HIV-associated lipodystrophy, a condition that severely impacts quality of life and metabolic health. Thi…
These findings suggest that GHRH therapy could represent a novel therapeutic strategy for improving cardiac function and quality of life in older adults with congestive heart failure and reduced growth hormone effect.…
This study provides compelling evidence that tesamorelin could be a highly effective pharmacological intervention for MASLD, addressing a critical unmet medical need. The significant reduction in liver fat observed su…
The intent behind this withdrawn study highlights a critical unmet need: finding effective treatments for sleep-disordered breathing in patients with lipodystrophy. If Tesamorelin could demonstrably improve sleep apne…
These findings, if confirmed upon publication, would establish tesamorelin as a promising therapeutic option for NAFLD in obese individuals, addressing a critical unmet medical need. Given the high prevalence of NAFLD…
This foundational Phase 1 study is critical because it provides essential data on how Tesamorelin behaves in HIV positive patients, a population with unique metabolic considerations. The successful characterization of…
The potential for Tesamorelin to augment exercise benefits in HIV-positive individuals is highly significant. If successful, this intervention could offer a novel and more effective strategy to combat frailty and phys…
Understanding Tesamorelin's short-term effects in healthy individuals is crucial for broadening its potential therapeutic applications beyond HIV-associated lipodystrophy. If Tesamorelin can safely enhance GH secretio…
This study, had it been completed, could have provided crucial evidence for a novel therapeutic strategy to mitigate cardiovascular risk in individuals with abdominal obesity. By demonstrating a direct link between GH…
The withdrawal of this study highlights a persistent gap in research for effective treatments for TBI-related insomnia, a condition that significantly impacts the quality of life for service members and veterans. Had …
This research highlights tesamorelin's potential as a targeted therapeutic option for managing HIV lipodystrophy, offering more than just cosmetic benefits. The significant reduction in visceral fat, coupled with impr…
This study represents a significant advancement in the fight against doping in sports, specifically targeting growth hormone releasing hormone synthetic analogs. By identifying and characterizing previously unknown me…
This highly sensitive and robust nano LC-Q/Orbitrap MS method represents a significant advancement in the detection of GHRH and its analogs, which are frequently abused performance-enhancing drugs. The enhanced sensit…
This study is significant because it confirms the sustained efficacy and long-term safety of TH9507 (Tesamorelin) as a targeted treatment for HIV-associated lipodystrophy, a challenging side effect of ART. Reducing vi…